Details
Stereochemistry | ACHIRAL |
Molecular Formula | C17H16FN3O2S |
Molecular Weight | 345.391 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CNCC1=CN(C(=C1)C2=CC=CC=C2F)S(=O)(=O)C3=CC=CN=C3
InChI
InChIKey=BFDBKMOZYNOTPK-UHFFFAOYSA-N
InChI=1S/C17H16FN3O2S/c1-19-10-13-9-17(15-6-2-3-7-16(15)18)21(12-13)24(22,23)14-5-4-8-20-11-14/h2-9,11-12,19H,10H2,1H3
Molecular Formula | C17H16FN3O2S |
Molecular Weight | 345.391 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.takeda.com/news/2015/20150226_6922.htmlCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/25744862|
https://www.ncbi.nlm.nih.gov/pubmed/20624992
Sources: https://www.takeda.com/news/2015/20150226_6922.html
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/25744862|
https://www.ncbi.nlm.nih.gov/pubmed/20624992
Vonoprazan (Vonoprazan fumarate or TAK-438) under brand name Takecab, discovered by Takeda, is a new medicine for treating acid-related diseases with a novel mechanism of action called potassium-competitive acid blockers (P-CABs) which competitively inhibits the binding of potassium ions to H+,K+-ATPase (also known as the proton pump) in the final step of gastric acid secretion in gastric parietal cells. The drug is approved in Japan for the treatment of acid-related diseases, including gastric ulcer, duodenal ulcer, reflux esophagitis and Adjunct to Helicobacter pylori eradication in the case of Helicobacter pylori gastritis.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25744862
Curator's Comment: # Takeda
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095173 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20624992 |
0.003 µM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | TAKECAB Approved UseUnknown |
|||
Curative | TAKECAB Approved UseUnknown |
|||
Curative | TAKECAB Approved UseUnknown |
|||
Primary | TAKECAB Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26369775
Orally at 20 mg once daily for the treatment of gastroduodenal ulcer, at 20 and 10 mg once daily for the treatment and secondary prevention of reflux esophagitis, respectively, at 10 mg once daily for the secondary prevention of low-dose aspirin- or non-steroidal anti-inflammatory drug-induced peptic ulcer, and at 20 mg twice daily in combination with clarithromycin and amoxicillin for the eradication of Helicobacter pylori.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20624992
TAK-438 (Vonoprazan) inhibited H(+),K(+)-ATPase activity in porcine gastric microsomes with IC(50) values of 0.019 μM at pH 6.5. The inhibitory activity of TAK-438 was unaffected by ambient pH. The inhibition by TAK-438 was reversible and achieved in a K(+)-competitive manner.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 01:55:59 GMT 2023
by
admin
on
Sat Dec 16 01:55:59 GMT 2023
|
Record UNII |
1R5L3J156G
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29701
Created by
admin on Sat Dec 16 01:55:59 GMT 2023 , Edited by admin on Sat Dec 16 01:55:59 GMT 2023
|
||
|
NCI_THESAURUS |
C29723
Created by
admin on Sat Dec 16 01:55:59 GMT 2023 , Edited by admin on Sat Dec 16 01:55:59 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2604577
Created by
admin on Sat Dec 16 01:55:59 GMT 2023 , Edited by admin on Sat Dec 16 01:55:59 GMT 2023
|
PRIMARY | |||
|
15981397
Created by
admin on Sat Dec 16 01:55:59 GMT 2023 , Edited by admin on Sat Dec 16 01:55:59 GMT 2023
|
PRIMARY | |||
|
m11860
Created by
admin on Sat Dec 16 01:55:59 GMT 2023 , Edited by admin on Sat Dec 16 01:55:59 GMT 2023
|
PRIMARY | |||
|
9535
Created by
admin on Sat Dec 16 01:55:59 GMT 2023 , Edited by admin on Sat Dec 16 01:55:59 GMT 2023
|
PRIMARY | |||
|
4993
Created by
admin on Sat Dec 16 01:55:59 GMT 2023 , Edited by admin on Sat Dec 16 01:55:59 GMT 2023
|
PRIMARY | |||
|
HI-57
Created by
admin on Sat Dec 16 01:55:59 GMT 2023 , Edited by admin on Sat Dec 16 01:55:59 GMT 2023
|
PRIMARY | |||
|
1R5L3J156G
Created by
admin on Sat Dec 16 01:55:59 GMT 2023 , Edited by admin on Sat Dec 16 01:55:59 GMT 2023
|
PRIMARY | |||
|
1R5L3J156G
Created by
admin on Sat Dec 16 01:55:59 GMT 2023 , Edited by admin on Sat Dec 16 01:55:59 GMT 2023
|
PRIMARY | |||
|
Vonoprazan
Created by
admin on Sat Dec 16 01:55:59 GMT 2023 , Edited by admin on Sat Dec 16 01:55:59 GMT 2023
|
PRIMARY | |||
|
100000181475
Created by
admin on Sat Dec 16 01:55:59 GMT 2023 , Edited by admin on Sat Dec 16 01:55:59 GMT 2023
|
PRIMARY | |||
|
C152911
Created by
admin on Sat Dec 16 01:55:59 GMT 2023 , Edited by admin on Sat Dec 16 01:55:59 GMT 2023
|
PRIMARY | |||
|
881681-00-1
Created by
admin on Sat Dec 16 01:55:59 GMT 2023 , Edited by admin on Sat Dec 16 01:55:59 GMT 2023
|
PRIMARY | |||
|
DTXSID20236869
Created by
admin on Sat Dec 16 01:55:59 GMT 2023 , Edited by admin on Sat Dec 16 01:55:59 GMT 2023
|
PRIMARY | |||
|
DB11739
Created by
admin on Sat Dec 16 01:55:59 GMT 2023 , Edited by admin on Sat Dec 16 01:55:59 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BINDER->LIGAND |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
CUMULATIVE EXCRETION |
URINE
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
EXCRETED UNCHANGED |
URINE
|
||
|
TARGET -> INHIBITOR |
reversible and potassium-competitive manner with a potency of inhibition approximately 350 times higher than the proton pump inhibitor, lansoprazole.
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
||||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||